Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

2,130.00p
   
  • Change Today:
    -44.00p
  • 52 Week High: 3,170.00
  • 52 Week Low: 1,966.00
  • Currency: UK Pounds
  • Shares Issued: 66.54m
  • Volume: 173,570
  • Market Cap: £1,417.29m
  • RiskGrade: 128
  • Beta: 0.01
Select chart: 1 week | 6 month
 

Current

1 week

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-26 676.01 93.21 104.89p 20.3 0.7 +28% 34.60p 0.0%
30-Jun-27 686.30 88.90 103.60p 20.6 n/a -1% 35.79p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

Trends & Recommendations

  Current 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago
Revenue (£m)
30-Jun-2027 686 686 n/a n/a 733 n/a
30-Jun-2028 n/a n/a n/a n/a 768 n/a
 
Earnings
30-Jun-2027 103.60p 103.82p n/a n/a 104.76p n/a
30-Jun-2028 n/a n/a n/a n/a 114.15p n/a
 
Dividend
30-Jun-2027 35.79p 35.88p n/a n/a 35.66p n/a
30-Jun-2028 n/a n/a n/a n/a 36.35p n/a
 
Recommendations
Strong Buy 5 5 0 0 6 0
Buy 1 1 0 0 2 0
Neutral 1 1 0 0 2 0
Sell 1 1 0 0 0 0
Strong Sell 0 0 0 0 0 0
No. of Brokers 8 8 0 0 10 0
 
Average Rec 8.12 8.12 n/a n/a 8.50 n/a

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Broker estimates sourced from FactSet Estimates +44 (0) 20 3009 7000. FactSet Estimates calculate consensus using only those estimates changed or actively validated within the last 75 days.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price 2,130.00p
Change Today -44.00p
% Change -2.02 %
52 Week High 3,170.00
52 Week Low 1,966.00
Volume 173,570
Shares Issued 66.54m
Market Cap £1,417.29m
Beta 0.01
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.49% below the market average92.49% below the market average92.49% below the market average92.49% below the market average92.49% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
78.22% above the market average78.22% above the market average78.22% above the market average78.22% above the market average78.22% above the market average
90.91% above the sector average90.91% above the sector average90.91% above the sector average90.91% above the sector average90.91% above the sector average
Income
98.6% below the market average98.6% below the market average98.6% below the market average98.6% below the market average98.6% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
91.76% below the market average91.76% below the market average91.76% below the market average91.76% below the market average91.76% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 5
Buy 1
Neutral 1
Sell 1
Strong Sell 0
Total 8
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 05-Mar-26 06-Nov-25
Paid 27-Mar-26 05-Dec-25
Amount 11.20p 21.70p

Trades for 17-Jul-2026

Time Volume / Share Price
16:49 5 @ 2,138.00p
16:36 35,307 @ 2,130.00p
16:35 24,227 @ 2,130.00p
16:35 68,810 @ 2,130.00p
16:35 120 @ 2,130.00p

Genus Key Personnel

CEO Jorgen Kokke
CFO Andy Russell

Top of Page